2.20
price down icon5.98%   -0.14
after-market アフターアワーズ: 2.24 0.04 +1.82%
loading
前日終値:
$2.34
開ける:
$2.325
24時間の取引高:
109.45K
Relative Volume:
0.72
時価総額:
$7.92M
収益:
-
当期純損益:
$-15.47M
株価収益率:
-4.40
EPS:
-0.5
ネットキャッシュフロー:
$-13.51M
1週間 パフォーマンス:
+18.92%
1か月 パフォーマンス:
+44.26%
6か月 パフォーマンス:
-34.91%
1年 パフォーマンス:
-66.91%
1日の値動き範囲:
Value
$2.14
$2.38
1週間の範囲:
Value
$1.82
$2.39
52週間の値動き範囲:
Value
$1.30
$18.39

Nls Pharmaceutics Ltd Stock (NLSP) Company Profile

Name
名前
Nls Pharmaceutics Ltd
Name
セクター
Healthcare (1170)
Name
電話
-
Name
住所
-
Name
職員
1
Name
Twitter
Name
次回の収益日
Name
最新のSEC提出書
Name
NLSP's Discussions on Twitter

NLSP を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
NLSP
Nls Pharmaceutics Ltd
2.20 8.34M 0 -15.47M -13.51M -0.50
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Nls Pharmaceutics Ltd (NLSP) 最新ニュース

pulisher
May 30, 2025

Short Interest in NLS Pharmaceutics Ltd. (NASDAQ:NLSP) Decreases By 56.6% - Defense World

May 30, 2025
pulisher
May 21, 2025

NLS Pharmaceutics to present Mazindol study at ASCP Meeting By Investing.com - Investing.com South Africa

May 21, 2025
pulisher
May 21, 2025

NLS Pharmaceutics to present Mazindol study at ASCP Meeting - Investing.com Australia

May 21, 2025
pulisher
May 21, 2025

NLS Pharmaceutics (NLSP) to Showcase Promising Data on Mazindol ER | NLSP Stock News - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Breakthrough Clinical Data: New Drug Shows Dual Action Against Fentanyl Addiction and Withdrawal - Stock Titan

May 21, 2025
pulisher
May 14, 2025

NLS Pharmaceutics (NASDAQ:NLSP) Trading Down 0.6% – Should You Sell? - Defense World

May 14, 2025
pulisher
May 05, 2025

NLS Pharmaceutics Extends Merger Agreement with Kadimastem - TipRanks

May 05, 2025
pulisher
May 01, 2025

NLS Pharmaceutics Delays Yearly Report Filing - TipRanks

May 01, 2025
pulisher
Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 26, 2025

Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 25, 2025

NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split - ACCESS Newswire

Apr 25, 2025
pulisher
Apr 24, 2025

NLS Pharmaceutics Announces Board Resignation Amid Restructuring Efforts - TipRanks

Apr 24, 2025
pulisher
Apr 18, 2025

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics (PR Newswire) - Aktiellt

Apr 18, 2025
pulisher
Apr 18, 2025

Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS (PR Newswire) - Aktiellt

Apr 18, 2025
pulisher
Apr 16, 2025

NLS and Kadimastem: Swiss-israeli merger in ALS - European Biotechnology Magazine

Apr 16, 2025
pulisher
Apr 15, 2025

NLS Pharmaceutics Study Suggests Mazindol May Help Treat Fentanyl Use Disorder - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

NLS Pharmaceutics (NLSP): Promising Preclinical Results for Mazi - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

NLS Pharmaceutics Reports Positive Results in Fentanyl Study - TipRanks

Apr 15, 2025
pulisher
Apr 15, 2025

Nls Pharmaceutics Announces Positive Results From Study Ko-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward In Animal Models - MarketScreener

Apr 15, 2025
pulisher
Apr 15, 2025

NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models - Quantisnow

Apr 15, 2025
pulisher
Apr 15, 2025

NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models (PR Newswire) - Aktiellt

Apr 15, 2025
pulisher
Apr 14, 2025

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics - ADVFN

Apr 14, 2025
pulisher
Apr 06, 2025

NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest - ACCESS Newswire

Apr 06, 2025
pulisher
Apr 03, 2025

NLSP Stock Touches 52-Week Low at $1.73 Amid Steep Annual Decline - MSN

Apr 03, 2025
pulisher
Apr 02, 2025

Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements - ACCESS Newswire

Apr 02, 2025
pulisher
Mar 31, 2025

What's Going On With NLS Pharmaceutics Shares Monday? - Benzinga

Mar 31, 2025
pulisher
Mar 31, 2025

NLS Pharmaceutics Secures $3 Million Financing and $25 Million Equity Facility - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

NLS Pharmaceutics secures $2M for Kadimastem merger - Investing.com

Mar 31, 2025
pulisher
Mar 31, 2025

NLS Pharmaceutics secures $2M for Kadimastem merger By Investing.com - Investing.com Canada

Mar 31, 2025
pulisher
Mar 31, 2025

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement - StreetInsider

Mar 31, 2025
pulisher
Mar 25, 2025

NLSP stock touches 52-week low at $1.47 amid market challenges By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 25, 2025

NLSP stock touches 52-week low at $1.47 amid market challenges - Investing.com India

Mar 25, 2025
pulisher
Mar 16, 2025

NLS Pharmaceutics Ltd. (NASDAQ:NLSPW) Short Interest Down 31.6% in February - Defense World

Mar 16, 2025
pulisher
Mar 10, 2025

NLS Pharmaceutics announces merger with Kadimastem By Investing.com - Investing.com Canada

Mar 10, 2025
pulisher
Mar 10, 2025

NLS Pharmaceutics Announces Strategic Merger and Advances in Therapeutic Pipeline - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

NLS Pharmaceutics CEO Issues Letter to Shareholders - Quantisnow

Mar 10, 2025
pulisher
Mar 10, 2025

NLS Pharmaceutics announces merger with Kadimastem - Investing.com India

Mar 10, 2025
pulisher
Mar 05, 2025

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger - Marketscreener.com

Mar 05, 2025
pulisher
Mar 04, 2025

NLSP stock touches 52-week low at $1.71 amid steep annual decline - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

NLSP stock touches 52-week low at $1.71 amid steep annual decline By Investing.com - Investing.com South Africa

Mar 04, 2025
pulisher
Mar 01, 2025

NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq - ACCESS Newswire

Mar 01, 2025
pulisher
Feb 28, 2025

NLS Pharmaceutics Announces Compliance with Nasdaq Bid Price Requirement - ACCESS Newswire

Feb 28, 2025
pulisher
Feb 28, 2025

AEX-2 increases total wake duration in mouse model - BioWorld Online

Feb 28, 2025
pulisher
Feb 27, 2025

NLS Pharmaceutics Announces $20 Million Standby Equity Distribution Agreement and $2.5 Million Equity Investment - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

NLS Pharmaceutics reports progress in narcolepsy treatment By Investing.com - Investing.com South Africa

Feb 27, 2025

Nls Pharmaceutics Ltd (NLSP) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
大文字化:     |  ボリューム (24 時間):